Hemoglobinopathies Market Share, Analysis, Trends To 2022 by Grand View Research, Inc.

Global hemoglobinopathies market is expected to reach over USD 8.82 billion by 2022 according to a new report by Grand View Research Inc. Rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E is estimated to be the high impact rendering drivers of the market. According to the WHO, hemoglobin disorders are endemic in over 60% of 229 countries affecting over 70% of births. It is also reported that minimum 5% of the world population are carriers of significant variation.
Prevalence of hemoglobinopathies is high in low-income countries such as Sub Saharan region and South East Asia. 85% of the affected population in the U.S. and Europe has ancestral base in these regions.
Governments are collaborating with local institutes to undertake awareness programs for curbing the effect of hemoglobinopathies-related mortality rate. For instance, Thalassemia Data Collection Project and Registry and Surveillance System for Hemoglobinopathies (RuSH) projects were started in 2010 by the Centers for Disease Control and Prevention (CDC).
Low level of hygiene, insufficient healthcare infrastructure, and lesser awareness levels are some key factors attributing to increase in base of target population in low-income regions such as South East Asia, Mediterranean basin, and Africa.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/hemoglobinopathies-market

 U.S. sickle cell disease market, by therapy, 2012-2022, (USD Million)

Further key findings from the study suggest:

• The market for Sickle Cell Disease (SCD) was the largest with revenue valued at over USD 2,290.0 million in 2014. Rising prevalence of hemoglobinopathies and presence of strong product pipeline for sickle cell anemia such as HQK-1001 and Luspatercept are growth promoting factors of this market.
• Genetic testing for diagnosis of sickle cell disorders is expected to witness lucrative growth over the forecast period. It is estimated to grow at a CAGR of around 7.0%. Increasing awareness levels among people coupled with government programs such as the National Sickle Cell Disease Control Program conducted by the WHO in Africa are anticipated to enhance the usage rates for diagnostic tests pertaining to SCD.
• Hydroxyurea was one of the dominating segments of the SCD therapy market owing to the presence of the FDA-approved drugs such as Droxia and Hydrea by Bristol Myers Squib. SCD. Thalassemia market holds an extensive product portfolio in pipeline and their expected commercialization is anticipated to drive market growth. For instance, The Ellis Lab is developing a gene therapy for SCD in collaboration with Dr. Victor Garcia
• Blood tests including cell blood count and iron studies are the widely used techniques for diagnosis of thalassemia. On the other hand, pre-implant genetic testing is estimated to grow at lucrative growth rate over 8.5% in the next six years owing to rising base of health conscious population and increasing healthcare expenditure.
• The market for blood transfusion was the largest with revenues valued at over USD 1,408.0 million in therapeutic segment owing to, high acceptance level of this treatment option and significant success rate. It is estimated that around 85% of infants below five years suffering from thalassemia die due to insufficient blood transfusion.
• North America dominated the overall hemoglobinopathies market in terms of revenue in 2014 at over USD 1,212.0 million. Growing prevalence of blood disorders, favorable government programs, and high level of awareness among healthcare professionals and patients for hemoglobinopathies-related genetic testing are factors attributing to the major share of this market.
• Asia Pacific market is expected to witness lucrative growth over the forecast period with a CAGR of over 10% owing to the presence of high unmet clinical needs, improving healthcare infrastructure, and rising economic levels. Moreover, introduction of low-cost diagnostic alternatives will enhance adoption rates for hemoglobinopathies diagnostics market. 

Browse All Reports of this category @ http://www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the hemoglobinopathies market on the basis of type, diagnostics, and therapeutics:

Global Hemoglobinopathies Therapy Outlook (Revenue, USD Million), 2012 – 2022

• Thalassemia
• Alpha thalassemia
• Beta thalassemia
• Sickle cell disease
• Hemoglobin variants diseases

Global Hemoglobinopathies Diagnosis Outlook (Revenue, USD Million), 2012 – 2022

• Thalassemia
• Alpha thalassemia
• Beta thalassemia

• Sickle cell disease
• Hemoglobin variants diseases

Hemoglobinopathies Regional Outlook (Revenue, USD Million), 2012 – 2022

• North America
• U.S.
• Canada

• Europe
• Germany
• UK
• Asia Pacific
• Japan
• China
• Latin America
• Brazil
• Mexico
• MEA
• South Africa

Electrophysiology Devices Market Analysis, Size, Segment To 2020 by Grand View Research, Inc.

Global Electrophysiology Devices Market is expected to reach USD 6.19 billion by 2020, according to a new study by Grand View Research, Inc. Increasing incidence rates of cardiac arrhythmias clubbed with growing global geriatric population base are some major drivers of this market. Though still in the budding stage, the electrophysiology devices market has witnessed a significant rise in usage rates in the recent times, with physicians increasingly gaining experience in ablation and diagnostics techniques. Introduction of technological advancements such as the development of nanostim leadless pacemaker, improvements in catheter diagnostics and imaging modalities are also expected to improve device usage rates.
Diagnostic electrophysiology catheters are expected to grow at a healthy rate of over 15.0% during the forecast period. Rapid growth witnessed in this segment is attributed to catheter ablation becoming the first line of treatment for many rhythm disorders owing to its ability to render success rates of over 95.0%.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/electrophysiology-devices-market

Further key findings from the study suggest:

• X-ray systems were the leading electrophysiology monitoring segment in 2013. Growing usage rates of digital and portable systems enhancing diagnostic and interventional capabilities of healthcare practitioners is one of the key growth drivers of this market.
• Catheters emerged as the largest treatment devices sub-segment in 2013. Extensive use of these devices in electrophysiology studies and rapidly rising volume of interventional procedures are some factors accounting for its large share.
• North America was the largest regional market in 2013, accounting for a share of over 30.0% in 2013. Presence of sophisticated healthcare infrastructure supporting large volumes of interventional procedures and high patient awareness levels are some factors attributing for its large share.  
• Asia Pacific is expected to present this market with lucrative future growth opportunities. The region has a large prevalence of patients with unmet medical needs. Rapidly improving healthcare infrastructure and expenditure levels in the emerging markets of India and China have now opened up new avenues for the manufacturers to capitalize on during the forecast period.
• Some key manufacturers of electrophysiology devices include Abbott Laboratories, Medtronic Inc., St. Jude Medical, Boston Scientific Corporation, and Biotronik SE & Co. KG.
• New product development via extensive R&D investments and expanding patient base by entering the untapped markets of India, China and Brazil are some key sustainability strategies adopted by these market players.

Browse All Reports of this category @ http://www.grandviewresearch.com/industry/medical-devices          

Small Animal Imaging (In-Vivo) Market Size, Segmentation To 2022: Grand View Research, Inc.

Global Small Animal Imaging (In-Vivo) market is expected to reach USD 1.2 billion by 2022, according to a new study by Grand View Research, Inc. Growing number of medical conditions requiring accurate research for development of treatment options is expected to enhance demand for small animal imaging (in-Vivo) over the forecast period. Importance of these devices in applications such as epigenetic research studies, drug receptor targeting, and defining mechanism of action is estimated to provide potential growth platform for this industry. The major factors driving the growth of small animal imaging (in-vivo) market are growing usage of multi-functional pre-clinical imaging, rising investments of CROs in pre-clinical studies, increasing number of pharmaceutical and research organizations and technical innovations such as high-resolution MRI with other modalities.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/small-animal-imaging-in-vivo-market

Further key findings from the study suggest:

• Optical imaging dominated the technology segment in 2014 in terms of revenue share of over 45%. Advantages associated with this technology such as easy and rapid operations and relatively lower costs compared to other devices are the factors attributing for its high share.
• Micro-MRI technology is expected to be the fastest growing, and is expected to grow at a lucrative CAGR of over 12.0% by 2022. Micro-MRI has wide applications during functional and anatomical analysis in developing mouse neonates and embryos.
• In term of applications, monitoring treatment response, bio-distribution, cancer cell detection, biomarkers, longitudinal studies and epigenetic studies are segments studied. In 2014, Bio-distribution and monitoring the treatment response dominated the overall market in terms of revenue share of over 33% and 25% respectively.
• The cancer cell detection segment is expected to show prominent growth rate owing to the rising global prevalence of cancer, and increasing government initiatives pertaining to cancer diagnostics research. Cancer cell detection application is expected to generate revenue of over USD 700 million by 2022, at a CAGR of over 12% from 2015 to 2022.
• North America dominated in terms of revenue in 2014 at 36.1% in 2014. Favorable platform for R&D pertaining to technological advancements, vast pre-clinical research, established healthcare infrastructure, and rising demand for rapid and advanced methods are the key factors attributing for the highest revenue generation in this region. European market held the second position owing to the large number of pharmaceutical and clinical research organizations and diagnostic device manufacturers.
• Asia Pacific regional market is expected to register significant growth over the forecast period with CAGR of over 11% owing to emerging economies, growing base of target population, and growing clinical research activities. Additionally, rising acceptance level for advanced medical devices is expected to provide potential growth platform for key players of this market.
• The key players in this industry include Thermo Fisher Scientific, Inc. Siemens AG, Mediso Medical Imaging Systems, Life Technologies Corporation, Promega Corporation, Miltenyi Biotech GmbH, Bruker Corporation, FujiFilm Holding Corporation, PerkinElmer Inc. and Aspect Imaging Ltd. Companies are developing novel products to sustain their market positions. For instance, Bruker Corporation has launched SKYSCAN 1176, In-vivo micro-CT, and Wrist MRI Machine from Aspect for effortless imaging.

Browse All Reports of this category @ http://www.grandviewresearch.com/industry/medical-devices

Grand View Research has segmented the global small animal imaging (In-Vivo) market on the basis of medium and region:
 Global Small Animal Imaging (In-Vivo) Technology Outlook (Revenue, USD Million, 2012 – 2022)

• Micro-magnetic resonance imaging
• Optical imaging
• Nuclear imaging
• Other imaging modalities

Global Small Animal Imaging (In-Vivo) Application Outlook (Revenue, USD Million, 2012 – 2022)

• Monitoring treatment response
• Bio-distribution
• Cancer cell detection
• Biomarkers
• Longitudinal studies
• Epigenetics

Small Animal Imaging (In-Vivo) Regional Outlook (Revenue, USD Million, 2012 – 2022)

• North America
• Europe
• Asia Pacific
• RoW

Guidewires Market Trends 2014 To 2020 by Grand View Research, Inc.

Global guidewires market is expected to reach USD 2,197.2 million by 2020, according to a new study by Grand View Research, Inc. Growing prevalence of target diseases coupled with growing geriatric population base is expected to drive guidewire demand over the next six years. Technology innovation across various product segments, in terms of flexibility, tip retention etc. is also expected to boost market demand by catering to the requirements of healthcare practitioners.

Coronary guidewires dominated the overall market in terms of revenue, estimated at USD 700.1 million in 2013. Coronary guidewires market is expected to grow on account increasing prevalence of cardiovascular diseases and the presence of high minimally invasive coronary procedure volumes. 

View summary of this report @
http://www.grandviewresearch.com/industry-analysis/guidewires-market

 Global coronary and peripheral guidewires market, 2012 – 2020 (USD Million)

Further key findings from the study suggest:

• Global guidewires demand was 16,645.9 thousand units in 2013 and is expected to reach 25,640.2 thousand units by 2020, growing at a CAGR of 6.4% from 2014 to 2020. 
• Peripheral guidewires are expected to remain as the second largest product segment after coronary guidewires during the forecast period. In terms of revenue, the market for peripheral guidewires is expected to grow at a CAGR of over 6.0% from 2014 to 2020 due to increasing prevalence of peripheral vascular diseases (PVDs), peripheral artery diseases (PADs), abdominal aortic aneurysms (AAA) and carotid artery stenosis (CAS).
• North America dominated the overall market in terms of revenue share in 2013 majorly on account of the presence of high prevalence levels of cardiovascular and neurovascular disorders and sophisticated healthcare infrastructure
• Asia Pacific is expected to be the fastest growing regional market for guidewires, driven by increasing demand for medical tourism in emerging markets of India and China and rapidly improving healthcare infrastructure.
• Some key market players of guidewires include Terumo Corporation, ASAHI INTECC, Abbott Laboratories, Medtronic Inc., Cordis Corporation, Boston Scientific Corporation, Covidien, B. Braun and Cook Medical.
• R&D spending has steadily increased over the last three years, in an attempt to develop technologically advanced and cost effective products and avoid barriers such as product recalls. In addition, R&D is also focused on the unmet needs of healthcare practitioners in consideration. Tip shape retention, flexibility and minimal wire perforation are the key requirements of healthcare practitioners.

Browse All Reports of this category @ http://www.grandviewresearch.com/industry/medical-devices

For the purpose of this study, Grand View Research has segmented the global guidewires market on the basis of product and region:

Global Guidewires Product Outlook (Volume, Thousand units; Revenue, USD Million, 2012 – 2020)

            • Coronary Guidewire

            • Peripheral Guidewire

            • Neurovascular Guidewire

            • Urology Guidewire

Guidewires Regional Outlook (Volume, Thousand units; Revenue, USD Million, 2012 – 2020)

            • North America

            • Europe

            • Asia Pacific

            • RoW